Zometa and Hepatic enzyme abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic enzyme abnormal is reported as a side effect among people who take Zometa (zoledronic acid), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Lasix, and have Hypercalcaemia of malignancy.

The phase IV clinical study analyzes which people have Hepatic enzyme abnormal when taking Zometa. It is created by eHealthMe based on reports of 71,074 people who have side effects when taking Zometa from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Hepatic enzyme abnormal?

Hepatic enzyme abnormal is found to be associated with 564 drugs and 577 conditions by eHealthMe. Check the latest studies of Hepatic enzyme abnormal.

On Jul, 30, 2026

71,074 people reported to have side effects when taking Zometa.
Among them, 34 people (0.05%) have Hepatic enzyme abnormal.

Could Zometa cause Hepatic enzyme abnormal?

Among these 34 people:

How long have people been on Zometa when they have Hepatic enzyme abnormal? *

What is the gender of people who have Hepatic enzyme abnormal when taking Zometa? *

female: 64.71 %
male: 35.29 %

What is the age of people who have Hepatic enzyme abnormal when taking Zometa? *

What are other drugs people take besides Zometa? *

What are other side effects people have besides Hepatic enzyme abnormal? *

Pain: 14 people, 41.18%
Bone Disorder: 13 people, 38.24%
Scoliosis (a medical condition in which a person's spine is curved from side to side): 13 people, 38.24%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 13 people, 38.24%
Infection: 12 people, 35.29%
Sepsis (a severe blood infection that can lead to organ failure and death): 12 people, 35.29%
Septic Shock (shock due to blood infection): 12 people, 35.29%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 12 people, 35.29%
Thrombocytopenia (decrease of platelets in blood): 12 people, 35.29%
Weight Decreased: 12 people, 35.29%

What are the existing conditions these people have? *

Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 11 people, 32.35%
Metastases To Bone (cancer spreads to bone): 8 people, 23.53%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 6 people, 17.65%
Metastases To Liver (cancer spreads to liver): 3 people, 8.82%
Bone Disorder: 2 people, 5.88%
Nausea (feeling of having an urge to vomit): 2 people, 5.88%
Liver Disorder (liver diseases): 2 people, 5.88%
High Blood Cholesterol: 2 people, 5.88%
Menstruation Irregular: 2 people, 5.88%
Gastrointestinal Stromal Tumor: 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and have Hepatic enzyme abnormal?

- Check whether Hepatic enzyme abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zometa:

Zometa (71,434 reports)

Browse all side effects of Zometa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic enzyme abnormal:

Hepatic enzyme abnormal (564 drugs)

Browse all the conditions that are associated with Hepatic enzyme abnormal:

Hepatic enzyme abnormal (577 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zometa) and Zometa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.